Balázs Szigeti
@psybalazs
Psychedelics | Placebo effect | Data science | Citizen science | DeSci | RWE @UCSF's @TrPR_program, @Imperial_PRG and @psy_dao
🚨🍄 Major new preprint alert 🍄🚨 I think these will be important results. They are not going make me popular with my #psychedelic in-group, please do not shoot the messenger! The premise of this pre-registered meta analysis (osf.io/preprints/psya…) is that it is biased to…
We should turn off the internet each night from 6pm until midnight, keeping its benefits while giving us a nightly detox from its harmful side effects. 🧵
🧠 New Cognation episode! We dive into the Psychedelic Sciences Conference 2025 + interview with @UCSF data scientist @psybalazs on the "unblinding" problem in psychedelic research. Why placebo effects get complicated when patients know they're tripping #PsychedelicScience
UPDATE: based on this paper's (tinyurl.com/4kutxyvf) QIDS-to-MADRS conversion, which is more sophisticated than my '% of max change' approach, in the pramipexole trial the between-arm difference was ~7 MADRS units, so approximately twice as large as for #psilocybin therapy…
Some context for the COMPASS phase 3 #psilocybin trial, where there was a -3.6 MADRS difference from placebo at week 6 (tinyurl.com/3ufxx29n). I accidently came across this recent paper (pubmed.ncbi.nlm.nih.gov/40602411/) on pramipexole (mirapex) augmentation for treatment resistant…
New paper thread! 🧵 Many have called for “enhanced” informed consent documents (ICD) for psychedelic research & treatments, with growing calls for tailored ICDs in the psychedelic bioethics lit. But how closely do ICDs in psychedelic clinical trials reflect these proposals?
Some context for the COMPASS phase 3 #psilocybin trial, where there was a -3.6 MADRS difference from placebo at week 6 (tinyurl.com/3ufxx29n). I accidently came across this recent paper (pubmed.ncbi.nlm.nih.gov/40602411/) on pramipexole (mirapex) augmentation for treatment resistant…
🍄🚨🍄🚨 Another day, another cool preprint from our group: An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression We enrolled individuals with #bipolar 2 (BD-II) currently experiencing a major #depressive episode. Participants must have…
Will never understand why the amount of psychedelics taken can be used as credential when discussing philosophical issues
Love this vision a guy had on LSD 👨🚀
OK, I have come around on this, instead of Psychedelic-assisted therapy, how about how about Therapy-assisted psychedelic? Gives more emphasis to the drug component of the treatment
Are You comfortable with “psychedelic assisted therapy” nomenclature? Some question the primacy it puts on “therapy”. Can we say yet which component is most influential?
My comments in the thread might be interpreted otherwise but I admire this work. It’s so good to present surprising results and get the critical juices going… It’s how we learn…
🚨🍄 Major new preprint alert 🍄🚨 I think these will be important results. They are not going make me popular with my #psychedelic in-group, please do not shoot the messenger! The premise of this pre-registered meta analysis (osf.io/preprints/psya…) is that it is biased to…
If you want to know how to solve the problem on the top, come to my talk at the bottom! I promise it will not be just 'lets try niacin'! 😉 (hope to) See you in Denver on June 19th from 10am! #PsychedelicScience2025 #PS2025
